Collaborator News

Advanced Search
  • Jan 19, 2017

    AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), a biotechnology company focused on enhancing productivity in aquaculture and a majority-owned subsidiary of Intrexon Corporation (NYSE: XON), announces that it has completed the listing of its common shares on the NASDAQ Stock Market and finalized the equity subscription from Intrexon...

  • Jan 5, 2017

    Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the U. S. Food and Drug Administration (FDA) has granted Fast Track designation to FCX-007, the Company’s clinical-stage candidate for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)—a rare, devastating genetic skin disease for which no FDA-approved therapies exist...

  • Dec 19, 2016

    Fibrocell Science, Inc. (NASDAQ:FCSC) today announced that John Maslowski has been appointed Chief Executive Officer (CEO) and Douglas Swirsky has been appointed Chairman of the Company’s Board of Directors, succeeding David Pernock effective immediately. In addition, Mr. Maslowski has been appointed to the Company’s Board...

  • Dec 15, 2016

    Oragenics (NYSE MKT:OGEN.BC), a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced it presented at the American Society for Microbiology (ASM) Conference on Antibacterial Development held at the Omni Shoreham Hotel in Washington, DC, on Dec. 11-14, 2016. The presentation, entitled “Engineering Improved Variants of Mutacin 1140 by Saturation Mutagenesis,” overviewed a library of over 400 different lantibiotic variants developed in collaboration with Intrexon Corporation (NYSE:XON) to derive useful structure/function data and further improve the therapeutic profile of this class of compounds...

  • Dec 13, 2016

    Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced that the United States Patent Office has granted U.S. Patent No. 9,512,204 which provides composition of matter coverage for SYN-005, the Company's preclinical drug candidate designed to treat or prevent the development of Pertussis (whooping cough), especially in infants. This patent, which is co-owned with Synthetic Biologics' Pertussis academic collaborator, The University of Texas at Austin (UT Austin), is also exclusively licensed to Synthetic Biologics. The patent covers, among others, the Company's monoclonal antibody, hu1B7, a component of SYN-005 which is the subject of an ongoing study funded by a grant from the Bill & Melinda Gates Foundation to UT Austin...


print email